Denmark - Pharmaceutical products
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 21 May 2019
- Opportunity publication date
- 11 April 2019
- Category
- 33600000
- Value of contract
- £5m-50m
- Your guide to exporting
Description
Procurement No: 1ATC Code: J01DH02Generic name: Meropenem (Vial)Pharmaceutical form: Powder for infusionfluidStrength: 500 mgUnit value: 3 gVolume in units: (Norway: 3750)(Denmark: 6695)(Iceland: 19)ATC Code: J01DH02Generic name: Meropenem (Vial)Pharmaceutical form: Powder for infusionfluidStrength: 1 gUnit value: 3 gVolume in units: (Norway: 65500) (Denmark: 1784490) (Iceland: 495).Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
- Opportunity closing date
- 21 May 2019
- Value of contract
- £5m-50m
About the buyer
- Address
- Amgros I/S Dampfærgevej 22 København Ø 2100 Denmark
- Contact
- udbud@amgros.dk
The deadline to apply for this opportunity has passed.
Visit the
opportunities page
to find another.